The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
Abstract
Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1-(7-36) amide (GLP-1) are glucose-dependent insulinotropic gut hormones that may explain the greater insulin secretory response with oral compared to i.v. glucose (incretin effect). To study their individual and combined contributions, in eight healthy volunteers, on separate occasions, synthetic human GIP (1 pmol/kg.min) and/or GLP-1 (0.3 pmol/kg.min) or placebo were infused i.v. (-30 to 120 min), while at 0 min, a glucose infusion "isoglycemic" to the profile after an oral glucose load of 50 g/400 mL was started. After the administration of 50 g oral glucose, immunoreactive GIP rose several-fold to 337 +/- 43 pmol/L, while there was only a transient (10-30 min) and moderate increment in immunoreactive GLP-1 (from basal, 25-30, to 41 +/- 4 pmol/L). Isoglycemic i.v. glucose infusions led to smaller B-cell responses (estimated incretin effect, 41 +/- 5%). With single infusions of GIP or GLP-1 (circulating concentrations, 464 +/- 73 and 54 +/- 3 pmol/L, respectively), B-cell responses were significantly augmented compared to i.v. glucose alone and were no longer significantly different from those after oral glucose. The combination of GIP and GLP-1 led to B-cell responses that were significantly higher than those with either hormone alone (additive mode of cooperation). Plasma GIP concentrations were similar after endogenous secretion (oral glucose) and i.v. infusion, while exogenously administered GLP-1 led to plasma levels that were maintained at an elevated level for a longer period during exogenous infusion than after stimulation by oral glucose. When, in seven volunteers, a lower dose (0.15 pmol/kg.min) of GLP-1 was infused during isoglycemic glucose infusion experiments only for the duration of elevated plasma levels in the oral glucose challenges (0-30 min), a significant, but transient, increment in insulin and C-peptide concentrations was observed, which was equivalent to 26 +/- 10% of the estimated incretin effect. Therefore, in conclusion, circulating GIP seems to make a major contribution to the incretin effect after oral glucose, and GLP-1 appears to mediate a smaller proportion. GIP and GLP-1 can interact in an additive manner in normal man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Intestinal Factors in the Control of Insulin Secretion
McINTYRE, N., HOLDSWORTH, C. D., & TURNER, D. S. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1317 · Cited by 381
Pancreatic and intestinal processing of proglucagon in man
Ørskov, C., Holst, J. J., Poulsen, S. S., & Kirkegaard, P. (1987) · Diabetologia · doi:10.1007/bf00274797 · Cited by 210
Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*
BRUBAKER, P. L. (1991) · Endocrinology · doi:10.1210/endo-128-6-3175 · Cited by 159
Secretion of Proglucagon-Derived Peptides in Response to Intestinal Luminal Nutrients*
ROBERGE, J. N., & Brubaker, P. L. (1991) · Endocrinology · doi:10.1210/endo-128-6-3169 · Cited by 154
Cleator, I. G. M., & Gourlay, R. H. (1975) · The American Journal of Surgery · doi:10.1016/0002-9610(75)90360-8 · Cited by 141
Cited by
Items 101–110 of 110
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
“In agreement with the existence of two parallel receptor systems expressed on the b-cells, the effects of GIP and GLP-1 on insulin secretion were found to be additive (29).”
BackgroundResultInfluentialPanunzi, S., Pompa, M., Borri, A., Piemonte, V., & De Gaetano, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237215 · Cited by 21
Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
Role of peptide hormones in the adaptation to altered dietary protein intake
Rose, A. J. (2019) · Nutrients · doi:10.3390/nu11091990 · Cited by 15
“GIP is mainly known to affect meal-induced glucose-stimulated pancreatic insulin secretion [31], GIP also affects postprandial adipose tissue lipid metabolism by adipose tissue action [32,33], but not gastric emptying [34].”
BackgroundDhesi, B., Chauhan, H., & Basu, A. (2013) · Practical Diabetes · doi:10.1002/pdi.1767 · Cited by 4
Metadata
- Authors
- Nauck, M. A.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1993-04-01
- Volume
- 76
- Issue
- 4
- Pages
- 912-917
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2080959651
- Cited by
- 506
- References
- 16
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.